ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Axe falls at biotech firms Achaogen and NewLink Genetics

by Rick Mullin
August 3, 2018 | APPEARED IN VOLUME 96, ISSUE 32

 

Antibacterial specialist Achaogen is reorganizing to focus on commercializing its antibiotic plazomicin in the U.S. The company will pare back R&D to two programs—a beta-lactam/beta-lactamase inhibitor combination and new aminoglycoside antibiotics. Eighty jobs, or 28% of the firm’s staff, will be eliminated. A raft of top managers will exit Achaogen as well. Meanwhile, immuno-oncology specialist NewLink Genetics will cut 25 jobs from its payroll, a workforce reduction of 30%, and focus research on projects in clinical development.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment